chloroquine diphosphate has been researched along with methylprednisolone in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatta, N; Imai, T; Sakai, H; Takata, M; Takehara, K; Tsutsui, K | 1 |
| Altinay, G; Ermantaş, N; Okten, O; Oktun, MT; Soy, M; Tunçbilek, N; Turgut, B | 1 |
| Bruch-Gerharz, D; Haust, M; Homey, B; Meller, S | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
4 other study(ies) available for chloroquine diphosphate and methylprednisolone
| Article | Year |
|---|---|
Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Complement C3; Complement System Proteins; Cyclosporine; Dapsone; Dermatologic Agents; Female; Humans; Immunoglobulin G; Immunoglobulin M; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Methylprednisolone; Prednisolone; Pruritus; Skin Diseases, Papulosquamous | 1996 |
Nocardiosis in a patient with primary anti-phospholipid syndrome.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Antirheumatic Agents; Ceftriaxone; Chloroquine; Female; Humans; Immunocompromised Host; Methylprednisolone; Nocardia Infections; Thrombocytopenia; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
[Light induced subacute cutaneous lupus erythematodes: diagnosis and management].
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents; Basement Membrane; Chloroquine; Drug Therapy, Combination; Epithelium; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Methylprednisolone; Photosensitivity Disorders; Skin; Tacrolimus | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |